News Author: Jennifer Smith Publish date: December 20, 2018
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
News Author: Jennifer Smith Publish date: December 13, 2018
The rate of major bleeding was similar with apixaban and dalteparin.
News Author: Jennifer Smith Publish date: November 30, 2018
Differentiation syndrome may be overlooked in AML patients taking enasidenib (Idhifa).
News Author: Jennifer Smith Publish date: November 28, 2018
The approval is based on results from the ADMIRAL trial.
News Author: Jennifer Smith Publish date: November 28, 2018
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
News Author: Jennifer Smith Publish date: November 21, 2018
The U.S. Food and Drug Administration has approved the hedgehog pathway inhibitor glasdegib (Daurismo) for use in combination with low...
News Author: Jennifer Smith Publish date: November 21, 2018
Venetoclax is approved in combination with azacitidine, decitabine, or low-dose cytarabine for certain AML patients.
News Author: Jennifer Smith Publish date: November 20, 2018
Emapalumab (Gamifant) is expected to be available in the U.S. in the first quarter of 2019.
News Author: Jennifer Smith Publish date: November 19, 2018
The researchers advised that risk should be reevaluated frequently as treatment is given.
News Author: Jennifer Smith Publish date: November 17, 2018
Among the patients treated at the recommended dosing schedule, the 6-month overall response rate was 79%, and the complete response rate was 44%.
News Author: Jennifer Smith Publish date: November 14, 2018
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News Author: Jennifer Smith Publish date: November 13, 2018
The FDA has cleared NEO Iris, an automated blood bank instrument for mid- to high-volume labs.
News Author: Jennifer Smith Publish date: November 9, 2018
Denosumab increased bone density, reduced pain, and decreased markers of bone remodeling in patients with transfusion-dependent thalassemia.
News Author: Jennifer Smith Publish date: November 8, 2018
Selinexor has received fast track designation to treat patients with previously treated DLBCL who are not eligible for certain therapies.
News Author: Jennifer Smith Publish date: November 8, 2018
The HemoScreen hematology analyzer can perform a complete blood count at the point of care.
